Monogram Orthopaedics Inc... (MGRM)
| Bid | 2.78 |
| Market Cap | 99.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.14M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -5.51 |
| Forward PE | -6.02 |
| Analyst | Strong Buy |
| Ask | 2.95 |
| Volume | 76,906 |
| Avg. Volume (20D) | 662,561 |
| Open | 2.91 |
| Previous Close | 2.99 |
| Day's Range | 2.81 - 2.99 |
| 52-Week Range | 1.82 - 4.90 |
| Beta | 1.66 |
About MGRM
Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for...
Analyst Forecast
According to 1 analyst ratings, the average rating for MGRM stock is "Strong Buy." The 12-month stock price forecast is $5.4, which is an increase of 92.17% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Monogram Technologies Inc. (MGRM) Q4 2024 Earnings Call TranscriptMonogram Technologies Inc. (NASDAQ:MGRM ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Larry Holub - Investor Relations Benjamin Sexson - Chief Executive Officer Noe...
2 weeks ago · accessnewswire.com
CORRECTION: Monogram Technologies Reports Full Year 2024 Financial ResultsThis Press Release is Acting as a Correction to the Financial Tables in the Previous Release Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Informatio...
